Background: Atrial fibrillation (AF) is a growing financial burden on the healthcare system. Cardiac computed tomographic angiography (CCTA) is needed for pulmonary vein mapping before AF ablation (AFA). CCTA has shown to be an alternative to transesophageal echocardiogram (TEE) to rule out left atrial appendage thrombus (LAAT) pre-AFA. We aim to examine the safety, costeffectiveness, and time-efficiency of utilizing CCTA alone to rule out LAAT before AFA.
from a LAAT, 5 preoperative imaging of the left atrium is essential to exclude the presence of a thrombus. In current clinical practice, this is done through transesophageal echocardiogram (TEE), which is considered to be the "gold standard" imaging tool and is performed usually within 24-48 hours of the procedure. 4, 6 Yet, TEE requires sedation and esophageal intubation and does not allow complete visualization and assessment of all of the pulmonary veins nor their precise relationship to other thoracic structures. Furthermore, TEE is a semi-invasive procedure associated with patient discomfort and not without complications such as esophageal perforation, which, while very infrequent, can potentially be life-threatening. 7 Therefore, prior to a catheter-based AF ablation procedure, patients often undergo evaluation with other imaging modalities such as CCTA, which increases the cost and time surrounding the procedure.
In a cost-analysis study examining Medicare fee-for-service data to evaluate Medicare expenditures before, during, and after catheter ablation for AF from July 2007 to December 2009, it was found that among 11,525 patients who underwent catheter ablation for AF, the mean overall expenditure on the day of the procedure was $14,455. 8 The mean imaging expenditure in the periprocedural period was $884, accounting for approximately 6% of mean Medicare expenditures for catheter ablation of AF. The challenge becomes determining how to slow the rate of increase in periprocedural costs while preserving high-quality care. In efforts to control expenditures, a cost-conscious clinician should utilize an intervention which provides high value, depending on whether its benefits justify its costs. Therefore, the first step is to decrease or eliminate care that offers no benefit and may even be harmful. 9 In light of that, CCTA has been increasingly used for LAAT detection.
Several studies investigated the use of CCTA in the assessment of LAAT in preprocedural evaluation for AF ablation. [10] [11] [12] [13] [14] A challenge with CCTA is that LAA filling defects may represent thrombus or incomplete contrast mixing with blood. Therefore, prebolus of contrast material with delay before the CCTA contrast bolus can help distinguish between thrombus and incomplete contrast mixing.
While prior studies showed noninferiority of CCTA to TEE, there are no studies to date examining the cost-effective and time-efficient advantages of safely eliminating the use of preprocedural TEEs. Therefore, we have devised a study to compare the cost and electrophysiology lab utilization time in patients who undergo both a TEE and CCTA, versus patients who undergo CCTA alone prior to the catheter ablation of AF procedure.
METHODS

Cohort selection
The study was approved by the Institutional Review Board for Human Subjects Research at the University of Buffalo. A retrospective (control) cohort was identified using a query of the electronic medical record. For that group, patients with ablation of AF who underwent both CCTA imaging and TEE prior to ablation during September 2014
to December 2015 at Buffalo General Hospital (BGH) and Gates Cardiovascular Institute (GVI) were identified. A comparable experimental cohort was recruited prospectively by consenting patients at the time of their outpatient CCTA referral at BGH/GVI during the period of March 2016-February 2017. Inclusion criteria for the prospective cohort were patients who have paroxysmal AF scheduled for an AF ablation (AFA) procedure, and were scheduled to undergo CCTA with LAAT rule out protocol within 3 days prior to their AFA. Exclusion criteria for that cohort were patients who: (1) refused to consent; (2) had long-persistent AF; (3) did not undergo AFA for reasons other than TEE or CCTA related or (4) patients with history of prior strokes or hypercoagulable state; and (5) patients who were found to have a LAAT or left atrial filling defects on CCTA had to undergo TEE and thus were also excluded from the experimental cohort. For patients who were found to be in AF at the time of the procedure, the clinical protocol and decision whether to perform a TEE was left to the discretion of the attending electrophysiologist who would be performing the ablation procedure. Figure 1 illustrates the study protocol for patient inclusion and exclusion.
CCTA imaging protocol and interpretation
Prior to the study period, preprocedure imaging with CCTA was the standard clinical practice for all eligible patients undergoing catheter ablation of AF at our facility in order to define pulmonary vein anatomy.
The imaging was performed with 320-multidetector scanner (Aquilion ONE, Toshiba Medical Systems,Ōtawara, Japan) in the craniocaudal direction and during breath hold. Scanning parameter were as follows: gantry rotation time 350 ms; tube potential, 100 kV for the retrospective cohort and 120 kV for the prospective cohort; integrated automatic tube current dose reduction utilizing SURE Exposure 3D; display field of view 220 mm 2 ; and slice thickness of 0.5 mm. A retrospective acquisition protocol was used in the retrospective cohort, while a prospective acquisition protocol was used for the prospective cohort.
The patient received an injection of 70 mL of iodinated contrast Omnipaque 350 (GE Healthcare, Wauwatosa, WI, USA) at 6 mL/s followed by 50-mL normal saline at 6 mL/s. For the initial scan, bolus tracking technique was performed visually with region of interest in the descending aorta. However, to improve the sensitivity of the study to rule out LAAT, delayed imaging was integrated into the standard protocol in the 
TEE and AFA procedural protocol
In the retrospective cohort, TEE was performed after patient had presented to the electrophysiology lab for the AF ablation. Patients were excluded if the TEE was performed the day before the ablation or outside the electrophysiology (EP) lab on the day of the procedure. A preplanned TEE was cancelled in the prospective group if CCTA delayed images confirmed no LAAT. Decision to continue or to hold preprocedural anticoagulation and antiarrhythmic therapy was left to the proceduralist's discretion. Activated clotting time of > 300 seconds was targeted in all cases. All patients were on anticoagulation postprocedure for at least the first month of follow-up. Pulmonary vein isolation was achieved by cryoballoon ablation strategy in all study cohorts. The procedure duration in the two cohorts was defined as the time patient entered the electrophysiology lab to the time they exited, which includes the TEE and AFA procedures.
Data collection and outcome measures
Data abstraction of the retrospective and prospective cohorts was Data collected on any incidental lung nodules were reported to the patients by phone calls to inform and advise them to discuss these incidental findings with their primary care physicians.
Statistical analysis
Demographic and clinical characteristics were summarized using descriptive statistics (means, standard deviations, and percentages) for both (CCTA+TEE and CCTA-only) groups and for the overall sample. Statistically significant differences between the groups on demographic and clinical measures were then determined using 2 tests for categorical data and Student's t-tests for continuous data. Finally, a set of analysis of variance (ANOVAs) was performed to determine if there were significant differences on the outcome measures (i.e., total cost, time in lab) between the CCTA+TEE and CCTA-only groups. Any demographic or clinical characteristics that were found to be statistically different between the groups were used as covariates in the ANOVA models. Prior to running the analyses, the distributions of all continuous measures were checked for any violations of normality (e.g., skewness, kurtosis). All alpha levels were set to 0.05 and all analyses were performed using SPSS v24 (IBM Corp., Armonk, NY, USA).
There were a total of 141 patients included in this study. The CCTA+TEE group had 71 patients, and 70 patients were recruited for the CCTA-only group. The baseline demographic and clinical characteristics are shown in Table 1 . The majority of the sample were white males, with a little over 60% of the sample being 60 years of age or older. Most of the sample was either overweight (33.3%) or obese (47.5%) and a little over half of the sample had a history of hypertension. The majority of the patients were considered to be high risk with a CHADS2VASC score of 2+. However, none of the patients had prior strokes. Eight patients in the CCTA-only group had CHADS2VASC of 4, with no patients having score above that. Over 80% of the sample was taking cardiac medication(s), with nearly one-third taking more than one medication. The only statistically significant differences between the CCTA+TEE and CCTA-only groups was history of hypertension and aspirin-only use, with the CCTA+TEE group having a significantly higher proportion of patients with history of hypertension and aspirinonly use than the CCTA-only group. The radiation dose (mSV) in the CCTA with delayed imaging was significantly lower when compared to CCTAs done without delayed imaging (8.5 vs 19.9, P < 0.001).
After 30 days from the procedure, with no patients lost to followup, there were no strokes or TIAs reported in the CCTA-only group, giving the use of CCTA as a LAAT rule-out tool a 100% negative predictive value (NPV). While no patients had a positive CCTA finding of a LAAT in the CCTA-only group, two patients had an equivocal finding of a hypointensity in the LAA on delayed imaging. These patients underwent a confirmatory TEE, and both subsequently had results that were negative for LAAT and went on to have the ablation procedures performed but were excluded from the final time-and cost-efficiency analysis. Since no patient had a positive CCTA for LAAT, its sensitivity and positive predictive value (PPV) in detecting one could not be determined.
The mean comparisons of the outcome measures between the CCTA+TEE and CCTA-only groups are shown in Table 2 . There were no significant violations of normality in the distributions of the outcome measures, so parametric tests (i.e., ANOVA) were considered appropriate. On average, the total cost in the CCTA-only group was $687 less than the CCTA+TEE groups. However, a nonsignificant trend toward reduction in the average total cost was seen in the CCTAonly group compared to the CCTA+TEE group (P = 0.06). When the cost was subdivided into imaging (CCTA) and procedural (AFA) costs, the CCTA+TEE group had a significantly lower cost of CCTA than the CCTA-only group. There was no significant difference in the cost of the AFA procedure between the two groups. The CCTA-only group required 60 minutes less time for lab tests than the CCTA+TEE group (P < 0.001).
We also performed additional analysis in regards to the oftenfound anomalous pulmonary vein anatomy (Supplementary Material   Table S1 ). There were only four patients in the retrospective group with anomalous veins, and 12 in the prospective group. Given the low number of patients in the retrospective group, the analysis was only performed in the prospective group. In the prospective group, Note: ACEi = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blocker; CCTA = cardiac computed tomography angiography; NOAC = new oral anticoagulant; SD = standard deviation; TEE = transesophageal echocardiogram.
TA B L E 2 Comparisons of procedure costs and lab time between CCTA+TEE and CCTA-only patients
CCTA + TEE (n = 71), SD CCTA-only (n = 70), SD P-value 
DISCUSSION
The results of the safety analysis in our study shows that the use of CCTA only with delayed imaging protocol is enough to rule out a LAAT in patients who are at low to intermediate risk of stroke related to AF. This is in agreement with prior studies such as the one conducted by Wang et al. 10 which showed that among 670 CCTA-negative patients for LAAT or stasis, 669 (99%) were negative by TEE with one false-negative CCTA in a patient with grade 2 stasis by TEE but no thrombus, yielding a NPV of 99.9%. The authors of that study concluded that it may be possible to eliminate TEE in up to 80% of AF ablation patients based on negative CCTA findings. A meta-analysis of published prospective studies comparing CCTA with TEE in detecting LAAT prior to March 2014 concluded that for patients with TEE intolerance or contraindications, CCTA may be an alternative method, especially when the delayed imaging, electrocardiogram gating and heart rate control were performed. 15 Our study gives further incentive to this method, as it showed improvement in the efficiency of the electrophysiology lab by 1 hour. However, we were not able to show a significant cost difference when TEE was eliminated from the preprocedural imaging protocol. The CCTA results are consistent with prior literature which shows that the sole use CCTA with delayed imaging is a safe and effective method in ruling out a LAAT, potentially obviating the need for TEE prior to AFA procedure. 10, 15 Prior literature showed that, when using confirmatory intracardiac echocardiography as the reference standard, the use of CCTA-alone with delayed imaging protocol had a 100% PPV, 100% NPV, 100% sensitivity, and a 100% specificity (when equivocal results were considered negative). 16 However, given that no patient had a positive LAAT on CCTA in our study, we could not determine the sensitivity or the PPV of using CCTA-only for detecting a LAAT. Nonetheless, this demonstrates that the incidence of LAAT or the development of periprocedural CVA/TIA is relatively low enough to give a low pretest probability warranting the safe use of CCTA only. However, given that no patient in the CCTA-only group has scored the CHADS2VASC above 4, we cannot extrapolate these findings to very high-risk patients as such. Furthermore, none of patients included in the CCTA-only cohort had a prior history of CVA/TIA or LAAT, and thus these patients may be too high risk to safely obviate the need for a TEE. We do also recognize that approximately two-thirds of the patients were on anticoagulation, making the pretest probability low for CVA. Nonetheless, it is also important to note that almost all patients in our study held their anticoagulant 1-3 days prior to the procedure (depending on the proceduralist's preference). Thus, one might argue that this puts them at a higher risk of a subsequent development of a LAAT which would otherwise be detected on TEE on the day of the procedure could be missed in the prospective (CCTAonly) cohort. The absence of CVAs in that cohort proves that doing a CCTA alone without a TEE on the day of the procedure is also safe in patients where the anticoagulant was held for up to 3 days prior to the procedure. Since the publication for uninterrupted dabigatran and feasibility and safety of uninterrupted apixaban in comparison to uninterrupted warfarin, clinical practice may have also begun to change. 17 Therefore, as more AFA are performed on uninterrupted anticoagulation in the future, performing CCTA 1-3 days prior to the ablation in patient cohort represented in our study, forgoing TEE would be feasible. Nonetheless, there is no clear delineation in the literature for the optimal timing of preprocedural CCTA when used for ruling out LAAT. Based on available data, 3 days appears to be the average time with variable practice on preprocedural continuation of anticoagulation in prior studies. 13, 16 Therefore, a future adequately powered, multicenter, placebo-controlled, randomized, double-blinded trial including high-risk patients, timing of preprocedural CCTA, and continued use of anticoagulant periprocedurally is needed to assess the safety of using CCTA-alone in ruling out LAAT prior to AFA procedure.
In regards to the cost analysis, there was no significant difference in the total cost of the procedure including imaging. This may be due to the large disparity in the cost of the procedure from one patient to another as illustrated by the standard deviation. While there was a nonsignificant trend in the reduction of total cost with lower cost in the CCTA-only group, this reduction is attributed to the lower cost of the CCTA in that group. The reason why CCTA was less expensive in the CCTA-only group compared to the CCTA+TEE group is likely due to the timing of cohort sampling. The CCTA+TEE group is a retrospective cohort of patients who, presenting during the prior time period, compared to the prospective CCTA-only cohort. During that time, the cost of CCTA was higher on average than the time when the prospective cohort was recruited. Given that our study protocol did not systematically time cardiac imagers' readings of the CCTAs, we cannot give objective data on the additional time to read the LAA with delayed imaging. However, a verbal survey with the cardiac imagers of our facility found that since a second set of images is acquired, the time to perform and read the study increases not more than a few minutes. For CCTA acquisition, it is increased by approximately 20 seconds. In the delayed CCTA images, the left heart structures are poorly or not opacified, and hence the focus is truly on evaluating the LAA. This small duration of time spent on evaluating the delayed images is of high yield as it considerably increased the confidence among the readers and the specificity in identifying the presence or absence of a LAA clot. Therefore, one may argue that when the images were difficult to call LAA filling defect due to contrast not making in time, or due to clot in CCTA without delayed imaging, the delayed images helped make that decision quicker and improved the specificity. The additional delayed imaging did not increase the radiation exposure in our study. While we acknowledge that there is a small incremental increase of radiation dose for delayed imaging, but when carefully protocoled, the whole procedure can be accomplished within an acceptable range of radiation exposure. In fact, the CCTA-only group with delayed imaging had a lower radiation exposure in our study. This difference can be attributed to the change in imaging protocol of our center during the time in which the CCTAs of the retrospective group (2014) (2015) and the CCTAs of the prospective group (2016-2017) were performed. A lower radiation dose and quality were adopted with the newer scans, and the method of acquisition was also changed from retrospective to a prospective acquisition protocol. This proves that an increased radiation dose with delayed imaging protocol can be avoided while maintaining sensitivity of the procedure.
Although we have attempted to streamline the AF ablation preimaging process in our study, patients still had to present a few days prior to the procedure for their cardiac computed tomography scan. This removed the flexibility in scheduling options for the patient.
Intracardiac echocardiography catheters have been utilized to visualize the LAA and for low risk patients in which 3D mapping system provide adequate anatomical pulmonary vein landmark, avoiding CCTA altogether may be a consideration for future studies.
In the prospective group, there was a significant prolongation in the EP lab utilization time in patients with an anomalous vein when compared to patients with normal veins (253 vs 179 minutes, P < 0.001).
This may have been due to differences to the approach of the procedure where supra-numerous or small caliber veins can involve more technically challenging methods for vein isolation. Very rarely, the electrophysiologist had to use radiofrequency energy in addition to the cryoablation to attain PV isolation but those patients had not met the inclusion criteria and, therefore, none of the study cohort had hybrid radiofrequency and cryoablation.
While this study is the first to examine and demonstrate the costeffectiveness and time-efficiency of safely eliminating the use of preprocedural TEEs, there were some limitations. Given that the two cohorts were sampled from two different periods, there may be temporally related confounding variables. For instance, the difference in timing of sampling between the two cohorts may be a factor as the analysis does not take into consideration possible inflation or deflation in the cost of the AFA procedure. The cost of an AFA procedure performed early in the CCTA+TEE group (i.e., September 2014) may have been less expensive compared to an AFA procedure performed during the time in which the CCTA-only group was recruited (i.e., February 2017), thus underestimating the cost reduction of eliminating the TEE. Our study also was not powered enough to capture any patients with a positive LAAT on CCTA; therefore, we could not determine the sensitivity or the PPV of using CCTA-only for detecting a LAAT. The power of the CCTA+TEE study group also does not allow us to closely examine TEE complications. Additionally, we did not have any stroke outcomes in the prospective group that is likely due to low incidence of thromboembolism in this patient cohort.
CONCLUSION
The use of CCTA-only for ruling out LAAT in patients undergoing AFA procedure can safely obviate the need for a TEE. While no significant cost reduction was detected by eliminating TEEs, there was a 60-minute reduction in electrophysiology lab utilization time. Whether these findings apply to high-risk patients remains to be determined.
Therefore, a future adequately powered, multicenter trial including high-risk patients is needed to assess the safety of using CCTA alone in ruling out LAAT prior to AFA procedure.
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